Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Inhibitors of Virion Maturation and Assembly

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

Immune Response Against Viral Pathogens

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Antimicrobial Proteins

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Editorial: The immune response to therapeutic antibodies.

Frontiers in immunology·2025

Same author

ETS2 repressor factor (ERF) is involved in T lymphocyte maturation acting as regulator of thymocyte lineage commitment.

Journal of leukocyte biology·2022

Same author

Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma.

Frontiers in immunology·2020

Same author

A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies.

Journal of immunology research·2017

Same author

Safety, Tolerability, and Immunogenicity of Interferons.

Pharmaceuticals (Basel, Switzerland)·2016

Same author

IFNAR signaling directly modulates T lymphocyte activity, resulting in milder experimental autoimmune encephalomyelitis development.

Journal of leukocyte biology·2015

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Adjuvant activity of type I interferons.

Michael G Tovey¹, Christophe Lallemand, George Thyphronitis

¹Laboratory of Viral Oncology, FRE2937 CNRS, Institut André Lwoff, 7 rue Guy-Moquet, F-94801 Villejuif, France. tovey@vjf.cnrs.fr

Biological Chemistry

|October 28, 2008

Summary

This summary is machine-generated.

Type I interferons (IFNs) enhance immune responses to vaccines by activating B-cells and improving antigen presentation. These potent adjuvants show promise for both parenteral and mucosal vaccine applications.

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Rescue of Recombinant Newcastle Disease Virus from cDNA

Rescue of Recombinant Newcastle Disease Virus from cDNA

Published on: October 11, 2013

Related Experiment Videos

Last Updated: Jun 28, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Rescue of Recombinant Newcastle Disease Virus from cDNA

Rescue of Recombinant Newcastle Disease Virus from cDNA

Published on: October 11, 2013

Area of Science:

Immunology
Vaccinology

Background:

Type I interferons (IFNs), primarily from plasmacytoid dendritic cells (pDCs), are key in innate immunity against pathogens.
IFNs promote myeloid dendritic cell maturation and antigen presentation, crucial for adaptive immunity.

Purpose of the Study:

To investigate the adjuvant properties of Type I IFNs in vaccine responses.
To explore the mechanisms underlying IFN-mediated enhancement of humoral and cellular immunity.

Main Methods:

Administration of Type I IFNs with influenza vaccine via intramuscular (i.m.) or intranasal routes.
Evaluation of antibody isotype switching, T-cell responses, and antigen-presenting cell trafficking.

Main Results:

Type I IFNs act as potent polyclonal B-cell activators, inducing strong humoral immune responses with isotype switching.
IFNs promote an IgG2a antibody response, indicative of Th1 immunity, when combined with influenza vaccine.
Oromucosal IFN administration enhances vaccine-induced antibody responses by improving antigen-presenting cell migration.

Conclusions:

Type I IFNs possess significant adjuvant activity, enhancing both humoral and cellular immunity.
Recombinant Type I IFNs are promising adjuvants for parenteral and mucosal vaccines.
IFN's adjuvant effects involve direct actions on immune cells and enhanced antigen presentation.